Skip to main content
. 2019 Jan 21;19:92. doi: 10.1186/s12885-019-5281-5

Fig. 3.

Fig. 3

Comparison of OS of patients in the LRRT and non-LRRT group (a) Low-risk patients (patients with undetectable EBV DNA level and satisfactory tumor response post-PCT) (b) High-risk patients (patients with detectable EBV DNA level or/and unsatisfactory tumor response post-PCT) (c) Landmark analyses of overall survival for long-term survivors of ≥1 year in low risk group (d) Landmark analyses of overall survival for long-term survivors of ≥1 year in high risk group